Plozasiran: First Approval
Drugs · 2026-05 · 86 (5) · 753-758
DOI: 10.1007/s40265-026-02293-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drugs, online erschienen am 06.03.2026. Verfasst von Yahiya Y Syed. Beteiligte Einrichtung: Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com. Hauptthemen laut MEDLINE: Hyperlipoproteinemia Type I, Apolipoprotein C-III, RNA, Small Interfering. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Plozasiran (Redemplo®) is a first-in-class GalNAc-conjugated small interfering RNA (siRNA) designed to reduce hepatic apolipoprotein C-III (ApoC3) production. It is being developed by Arrowhead Pharmaceuticals for the treatment of familial chylomicronemia syndrome (FCS), severe hypertriglyceridaemia and mixed hyperlipidaemia. Plozasiran degrades ApoC3 mRNA via RNA interference, reducing hepatic and serum ApoC3 levels and thereby enhancing catabolism and clearance of serum triglycerides. It received its first approval in the USA on 18 November 2025 as an adjunct to diet to reduce triglycerides in adults with FCS. This article summarizes the key milestones in the clinical development of plozasiran leading to its first approval for FCS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.
Zitieren
APA
Syed, Y. Y. (2026). Plozasiran: First Approval. Drugs, 86(5), 753-758. https://doi.org/10.1007/s40265-026-02293-2
Vancouver
Syed YY. Plozasiran: First Approval. Drugs. 2026;86(5):753-758. doi:10.1007/s40265-026-02293-2
BibTeX
@article{Syed2026,
author = {Syed, Yahiya Y},
title = {Plozasiran: First Approval},
journal = {Drugs},
year = {2026},
volume = {86},
number = {5},
pages = {753--758},
doi = {10.1007/s40265-026-02293-2}
}
EUVIMED